New combo therapy aims to control advanced lung cancer
NCT ID NCT02422381
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced non-small cell lung cancer who have already tried other treatments. Researchers are testing whether adding an experimental drug called MK-3475 to standard chemotherapy (gemcitabine) is safe and what dose works best. The goal is to control the disease and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Oncology & Hematology Care Clinic - Eastside
Portland, Oregon, 97213, United States
-
Providence Oncology & Hematology Care Clinic - Westside
Portland, Oregon, 97225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery